[Sinopharm Modern: A wholly-owned subsidiary received a drug registration certificate for bumetanide injection] On November 13, Sinopharm Modern (600420.SH) announced that the company’s wholly-owned subsidiary Sinopharm Rongsheng received the “Drug Registration Certificate” for bumetanide injection (2ml:1mg) approved and issued by the State Food and Drug Administration. This drug is mainly suitable for edema diseases, hypertension, prevention of acute renal failure, etc. In 2025, the sales of this drug in public medical institutions across the country will be 197 million yuan. The approval and registration of this new specification will further enrich the company's product portfolio, help enhance the company's comprehensive market competitiveness in related pharmaceutical fields, and will not have a significant impact on the company's current operating performance.